Patents Assigned to Tanabe Seiyaku Co., Ltd
-
Patent number: 8012731Abstract: The present invention is to provide a novel phosphodiesterase and a gene thereof, specifically, Type 11 phosphodiesterase (PDE11) and a gene thereof, more specifically, a phosphodiesterase selected from (A) a protein having an amino acid sequenced shown by SEQ.ID.NO: 2, SEQ.ID.NO: 4, SEQ.ID.NO: 6 or SEQ.ID.NO: 39, and (B) a protein having an amino acid sequence shown by SEQ.ID.NO: 2, SEQ.ID.NO: 4, SEQ.ID.NO: 6 or SEQ.ID.NO: 39 in which one or several amino acids are deleted, substituted or added, and having an activity of hydrolyzing a cyclic nucleotide, and a gene thereof, and a method of characterizing, identifying and selecting a phosphodiesterase inhibitor by using the same.Type: GrantFiled: December 20, 2007Date of Patent: September 6, 2011Assignee: Tanabe Seiyaku Co., Ltd.Inventors: Kenji Omori, Keizo Yuasa, Jun Kotera, Kotomi Oda, Hideo Michibata
-
Patent number: 7799929Abstract: The present invention is to provide a process for preparing a synthetic intermediate of biotin which is industrially advantageous, and discloses a process for preparing a compound represented by the formula (I): 1 wherein R1 and R2 may be the same or different from each other, and each represents hydrogen atom, a benzyl group which may have a substituent(s) on the benzene ring, a benzhydryl group which may have a substituent(s) on the benzen ring, or a trityl group which may have a substituent(s) on the benzene ring, R3 represents cyano group, carboxyl group, an alkoxycarbonyl group, an alkylthiocarbonyl group, or a carbamoyl group which may have a substituent, or a salt thereof which comprises subjecting a compound represented by the formula (II-a): 2 wherein the symbols have the same meanings as defined above, or a salt thereof to ring transformation.Type: GrantFiled: January 7, 2008Date of Patent: September 21, 2010Assignee: Tanabe Seiyaku Co., Ltd.Inventors: Masahiko Seki, Toshiaki Shimizu, Shin-ichi Yoshida, Masanori Hatsuda
-
Publication number: 20090069298Abstract: The present invention relates to a novel pyrazolo[1,5-a]pyrimidine compound of the formula [I]: wherein R1 and R2 are the same or different and an optionally substituted aryl group etc. Q is single bond, a methylene group or a group of the formula: —N(RQ)—, RQ is an alkyl group, Ring A is a substituted pyrazole ring fused to the adjacent pyrimidine ring having the following formula (A), (B) or (C), R3 and R4 are the same or different and a hydrogen atom, a cyano group etc. E is one of the following groups (i) to (v): R00 is an alkyl group, Q1 is a single bond etc., Q2 is a single bond or an alkylene group, one of R5 and R6 is a hydrogen atom or an alkyl group and the other is an alkyl group etc., one of R50 and R60 is a hydrogen atom or an alkyl group and the other is a hydrogen atom, an alkyl group etc., R51 is an alkyl group or an optionally substituted arylsulfonyl group, R61 is an alkylamino group or an azido group, or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: October 20, 2006Publication date: March 12, 2009Applicant: TANABE SEIYAKU CO., LTD.Inventors: Yasunori Moritani, Kimihiro Shirai, Mariko Oi
-
Publication number: 20090005355Abstract: The present invention is to provide a piperidine compound represented by the formula [I]: wherein Ring A is an optionally substituted benzene ring, Ring B is an optionally substituted benzene ring, R1 is hydrogen atom or a substituent for amino group, R2 is hydrogen atom, an optionally substituted hydroxyl group, an optionally substituted amino group, an optionally substituted alkyl group, a substituted carbonyl group or a halogen atom, Z is oxygen atom or —N(R3)—, R3 is hydrogen atom or an optionally substituted alkyl group, R4a and R4b may be the same or different, and each is hydrogen atom or an optionally substituted alkyl group, or may be bonded to each other at the both ends to form an alkylene group, or a pharmaceutically acceptable salt thereof, which has an excellent tachykinin receptor antagonistic action.Type: ApplicationFiled: July 1, 2005Publication date: January 1, 2009Applicant: Tanabe Seiyaku Co., Ltd.Inventors: Tsutomu Miyake, Takeshi Yamanaka, Hidetoshi Asai, Yoshihiro Terakawa
-
Patent number: 7385083Abstract: A potassium channel opener comprising a compound (e.g., pimaric acid) represented by the formula [I]: wherein R1, R2, R3, R4, R5, R6 and R7 are each independently hydrogen, alkyl, alkenyl, halogen, hydroxy, halogenated alkyl, hydroxyalkyl, aminoalkyl, alkoxy, aryl, heteroaryl, acyl, carboxyl, alkoxycarbonyl, hydroxamate, sulfo, carbamoyl, sulfonamide, aldehyde, or nitrile; or R4 and R5 may be bonded to each other to form a ring; or R6 and R7 may be bonded to each other to form a ring; and all of three bonds represented by are single bonds, or one of the three bonds is double bond and the other bonds are single bonds, or a physiologically acceptable salt thereof as an effective ingredient.Type: GrantFiled: September 17, 2003Date of Patent: June 10, 2008Assignee: Tanabe Seiyaku Co., Ltd.Inventors: Yuji Imaizumi, Tomohiko Ohwada
-
Publication number: 20080081817Abstract: A novel nitrogenous fused bicyclic compound represented by the following general formula [1] or a pharmacologically acceptable salt of the compound. They have excellent SK channel blocking activity and are useful as a medicine. [I] (In the formula, R0 represents hydrogen, halogeno, etc.; R1 represents a group represented by the formula (a) or (b); A represents a group represented by the formula (X) or (Y); D1, D2 and D3 each represents N or CH; R2 represents halogeno or optionally halogenated lower alkyl, etc.; R3 represents hydrogen or lower alkyl; and Q represents lower alkylene.Type: ApplicationFiled: July 22, 2005Publication date: April 3, 2008Applicant: Tanabe Seiyaku Co., Ltd.Inventors: Iwao Takamuro, Saburo Kawanami, Yasunori Tsuboi, Toshiyuki Himiyama, Yuko Hasegawa, Hideki Mochida, Kouji Nogi
-
Patent number: 7335778Abstract: The present invention is to provide a process for preparing a synthetic intermediate of biotin which is industrially advantageous, and discloses a process for preparing a compound represented by the formula (I): wherein R1 and R2 may be the same or different from each other, and each represents hydrogen atom, a benzyl group which may have a substituent(s) on the benzene ring, a benzhydryl group which may have a substituent(s) on the benzen ring, or a trityl group which may have a substituent(s) on the benzene ring, R3 represents cyano group, carboxyl group, an alkoxycarbonyl group, an alkylthiocarbonyl group, or a carbamoyl group which may have a substituent, or a salt thereof which comprises subjecting a compound represented by the formula (II-a): wherein the symbols have the same meanings as defined above, or a salt thereof to ring transformation.Type: GrantFiled: December 4, 2002Date of Patent: February 26, 2008Assignee: Tanabe Seiyaku Co., Ltd.Inventors: Masahiko Seki, Toshiaki Shimizu, Shin-ichi Yoshida, Masanori Hatsuda
-
Patent number: 7332487Abstract: The present invention is to provide an aliphatic nitrogen-containing 5-membered ring compound represented by the formula [I]: wherein symbols in the formula have the following meanings; A: —CH2— or —S—, B: CH or N, R1: H, a lower alkyl group, etc., X: a single bonding arm, —CO—, —Alk—CO—, —COCH2—, —Alk—O—, —O—CH2—, —SO2—, —S—, —COO—, —CON(R3)—, —Alk—CON(R3)—, —CON(R3)CH2—, —NHCH2—, etc., R3: hydrogen atom or a lower alkyl group, Alk: a lower alkylene group, and R2: (1) a cyclic group which may be substituted, (2) a substituted amino group, etc., provided that when X is —CO—, then B is N, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 15, 2006Date of Patent: February 19, 2008Assignee: Tanabe Seiyaku Co., Ltd.Inventors: Kosuke Yasuda, Hiroshi Morimoto, Saburo Kawanami, Masataka Hikota, Takeshi Matsumoto, Kenji Arakawa
-
Patent number: 7332317Abstract: The present invention is to provide a novel phosphodiesterase and a gene thereof, specifically, Type 11 phosphodiesterase (PDE11) and a gene thereof, more specifically, a phosphodiesterase selected from (A) a protein having an amino acid sequenced shown by SEQ.ID.NO: 2, SEQ.ID.NO: 4, SEQ.ID.NO: 6 or SEQ.ID.NO: 39, and (B) a protein having an amino acid sequence shown by SEQ.ID.NO: 2, SEQ.ID.NO: 4, SEQ.ID.NO: 6 or SEQ.ID.NO: 39 in which one or several amino acids are deleted, substituted or added, and having an activity of hydrolyzing a cyclic nucleotide, and a gene thereof, and a method of characterizing, identifying and selecting a phosphodiesterase inhibitor by using the same.Type: GrantFiled: December 22, 2000Date of Patent: February 19, 2008Assignee: Tanabe Seiyaku Co., Ltd.Inventors: Kenji Omori, Keizo Yuasa, Jun Kotera, Kotomi Oda, Hideo Michibata
-
Patent number: 7323337Abstract: Highly efficient gene transfer into primate-derived embryonic stem (ES) cells has successfully been achieved by using a simian immunodeficiency virus vector (SIV) pseudotyped with VSV-G protein, which is a surface glycoprotein of vesicular stomatitis virus (VSV) The present invention provides simian immunodeficiency virus vectors for gene transfer to primate ES cells. The method for gene transfer to primate ES cells using the vectors of the present invention is useful in, for example, research into embryology and disease, clinical applications, and experimental models for primates. The method is also useful in assaying and screening for genes and reagents able to enhance the specific differentiation of tissues or cells, and which are useful in preparing desired cells or tissues differentiated from ES cells.Type: GrantFiled: May 29, 2002Date of Patent: January 29, 2008Assignees: DNAVEC Research Inc., Tanabe Seiyaku Co., Ltd.Inventors: Yutaka Hanazono, Yasuji Ueda, Yasushi Kondo, Yutaka Suzuki
-
Patent number: 7282589Abstract: (S)-(?)-4-[(4-chlorophenyl)(2-pyridyl)methoxy]piperi-dine represented by the formula (IV): wherein * represents an asymmetric carbon.Type: GrantFiled: February 5, 2004Date of Patent: October 16, 2007Assignees: UBE Industries, Ltd., Tanabe Seiyaku Co., Ltd.Inventors: Jun-ichiro Kita, Shinji Takamura
-
Patent number: 7273868Abstract: 1. A cyclic compound of the formula (I) or a pharmacologically acceptable salt thereof, wherein X is ?CH— or ?N—, Y is —NH—, —NR4—, —S—, —O—, —CH?N—, —N?CH—, —N?N—, —CH?CH—, etc., R1 is a lower alkoxy group, an amino group, a heterocyclic ring containing N atom(s), or a hydroxy group substituted by a heterocyclic ring containing N atom(s) (each of which is optionally substituted), R2 is a lower alkylamino group which is optionally substituted by an aryl group, a lower alkoxy group which is optionally substituted by an aryl group, a lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), R3 is an aryl group, a heterocyclic ring containing N atom(s), a lower alkyl group, a lower alkoxy group, a cyclo lower alkoxy group, a hydroxy group substituted by a heterocyclic ring containing N atom(s), or an amino group (each of which is optionally substituted), and R3 and a substituent in Y may be combined to form a lactone ring.Type: GrantFiled: November 4, 2003Date of Patent: September 25, 2007Assignee: Tanabe Seiyaku Co., Ltd.Inventors: Koichiro Yamada, Kenji Matsuki, Kenji Omori, Kohei Kikkawa
-
Publication number: 20070185116Abstract: The present invention is to provide a bicyclic compound represented by the following formula: wherein Ring Q is pyridine or pyrimidine; Ring A is benzene or a heterocyclic ring; G is Ring B optionally having a substituent(s) R3, or an amino optionally substituted by one or two selected from the group consisting of alkyl(s), aralkyl(s) and cycloalkyl(s); Ring B is benzene, a heterocyclic ring, a cycloalkane or a cycloalkene; R1 is a group selected from the following formulae: R2 and R3 may be the same or different from each other, and each is cyano, nitro, etc.; m is 0, 1 or 2; R4 is hydrogen, a halogen, etc.; and R5 and R6 may be the same or different from each other, and each is hydrogen, an optionally substituted alkyl, etc., or a pharmaceutically acceptable salt thereof, which is a large conductance calcium-activated K channel opener useful for treatment of pollakiuria, urinary incontinence, etc.Type: ApplicationFiled: May 30, 2005Publication date: August 9, 2007Applicant: TANABE SEIYAKU CO., LTD.Inventors: Miki Hirai, Mari Kusama, Toshihiro Hosaka, Shuntarou Kohnomi
-
Publication number: 20070124826Abstract: A method of differentiation from an embryonic stem cell of a primate into a hematopoietic cell, comprising maintaining an embryonic stem cell of a primate under conditions suitable for induction of differentiation into a hematopoietic cell, transplanting the resulting cell into a fetus in a uterus of a pregnant sheep, rearing the fetus, administering a cytokine specific for a primate to a born lamb, and obtaining a hematopoietic cell of a primate from a sheep obtained by rearing the lamb, a method for producing a hematopoietic cell of a primate, a hematopoietic cell obtained by the method, and a method for producing a chimeric sheep which produces a hematopoietic cell of a primate, comprising maintaining an embryonic stem cell of a primate under conditions suitable for induction of differentiation into a hematopoietic cell, and transplanting the resulting cell into a fetus in a uterus of a pregnant sheep.Type: ApplicationFiled: August 24, 2004Publication date: May 31, 2007Applicant: TANABE SEIYAKU CO., LTD.Inventors: Yutaka Hanazono, Kyoko Sasaki
-
Patent number: 7220736Abstract: A cyclic compound of the formula (I) or a pharmacologically acceptable salt thereof, wherein X is ?CH— or ?N—, Y is —NH—, —NR4—, —S—, —O—, —CH?N—, —N?CH—, —N?N—, —CH?CH—, etc., R1 is a lower alkoxy group, an amino group, a heterocyclic ring containing N atom(s), or a hydroxy group substituted by a heterocyclic ring containing N atom(s) (each of which is optionally substituted), R2 is a lower alkylamino group which is optionally substituted by an aryl group, a lower alkoxy group which is optionally substituted by an aryl group, a lower alkoxy group substituted by an aromatic heterocyclic ring containing N atom(s), R3 is an aryl group, a heterocyclic ring containing N atom(s), a lower alkyl group, a lower alkoxy group, a cyclo lower alkoxy group, a hydroxy group substituted by a heterocyclic ring containing N atom(s), or an amino group (each of which is optionally substituted), and R3 and a substituent in Y may be combined to form a lactone ring.Type: GrantFiled: March 15, 2001Date of Patent: May 22, 2007Assignee: Tanabe Seiyaku Co., Ltd.Inventors: Koichiro Yamada, Kenji Matsuki, Kenji Omori, Kohei Kikkawa
-
Patent number: 7220430Abstract: The present invention is to provide a sustained release preparation comprising a drug-containing core substance and a multilayered coating layer covering the core substance, wherein all adjacent layers in the multilayered coating layer contain mutually different hydrophobic organic compound-water-soluble polymer mixtures; and, a method of producing a sustained release preparation, having a multilayered coating layer in which adjacent layers contain different hydrophobic organic compound-water-soluble polymer mixtures, which comprises spray-coating a solution containing a hydrophobic organic compound-water-soluble polymer mixture onto a drug-containing core substance, continuing to spray-coat a solution containing a different hydrophobic organic compound-water-soluble polymer mixture onto the resulting coating layer, and repeating this step.Type: GrantFiled: January 26, 2001Date of Patent: May 22, 2007Assignee: Tanabe Seiyaku Co., Ltd.Inventors: Takashi Ishibashi, Kengo Ikegami, Keigo Nagao, Hiroyuki Yoshino, Masakazu Mizobe
-
Publication number: 20070112029Abstract: Disclosed are a novel piperidine compound represented by the general formula [I] below which has an excellent tachykinin receptor antagonizing activity and pharmacologically acceptable salts thereof. [I] In the formula, ring A represents an optionally substituted benzene ring; ring B represents an optionally substituted benzene ring; R1 represents an optionally substituted hydroxyl group, a thiol group having a substituent, a sulfonyl group having a substituent, or a group represented by the following formula [II]: wherein R11 represents a carbonyl group having a substituent or a sulfonyl group having a substituent and R12 represents a hydrogen atom or an optionally substituted alkyl group; R2 represents a hydrogen atom or the like; Z represents an oxygen atom or a group represented by —N(R3)— wherein R3 represents an optionally substituted alkyl group or the like; R4a represents an optionally substituted alkyl group; and R4b represents an optionally substituted alkyl group.Type: ApplicationFiled: November 26, 2004Publication date: May 17, 2007Applicant: TANABE SEIYAKU CO., LTD.Inventors: Masami Takahashi, Tsutomu Miyake, Takeshi Yamanaka, Hidetoshi Asai, Rikako Kono
-
Publication number: 20070060545Abstract: A compound of the formula: wherein Ring A and Ring B are (1) Ring A is an optionally substituted unsaturated monocyclic heterocyclic ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, (2) Ring A is an optionally substituted benzene ring, and Ring B is an optionally substituted unsaturated monocyclic heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring, or (3) Ring A is an optionally substituted unsaturated fused heterobicyclic ring, wherein —NR— group and —CH2— group are both on the same ring of the unsaturated fused heterobicyclic ring, and Ring B is an optionally substituted monocyclic unsaturated heterocyclic ring, an optionally substituted unsaturated fused heterobicyclic ring, or an optionally substituted benzene ring; and R is a hydrogen atom, a lower alkyl group, a lower alkanoyl groType: ApplicationFiled: July 30, 2004Publication date: March 15, 2007Applicant: TANABE SEIYAKU CO., LTD.Inventors: Sumihiro Nomura, Toshiaki Sakamoto, Kiichiro Ueta
-
Publication number: 20070043113Abstract: The present invention relates to novel phenylalanine compounds, processes for their preparation, compositions comprising them and their use in the treatment or prevention of diseases capable of being modulated by the inhibition of cell adhesion.Type: ApplicationFiled: December 17, 2004Publication date: February 22, 2007Applicant: TANABE SEIYAKU CO., LTD.Inventors: Robert Ward, Charlotte Pradet, Ian Andrews
-
Patent number: 7160877Abstract: The present invention is to provide an aliphatic nitrogen-containing 5-membered ring compound represented by the formula [I]: wherein A represents —CH2— or —S—, R1 represents hydrogen atom, a lower alkyl group, a hydroxy lower alkyl group or a lower-alkoxy lower alkyl group, X represents —N(R3)—, —O— or —CO—, where R3 represents hydrogen atom or a lower alkyl group, and R2 represents (1) a cyclic group which may be substituted, or (2) an amino group which may be substituted, or a pharmaceutically acceptable salt thereof, a method for preparing the above-mentioned compound and a pharmaceutical composition comprising the above-mentioned compound as an effective ingredient.Type: GrantFiled: June 22, 2004Date of Patent: January 9, 2007Assignee: Tanabe Seiyaku Co., Ltd.Inventors: Kosuke Yasuda, Hiroshi Morimoto, Saburo Kawanami, Masataka Hikota, Takeshi Matsumoto, Kenji Arakawa